Last reviewed · How we verify
Verity Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Bacillus Calmette-Guerin: Strain TICE | Bacillus Calmette-Guerin: Strain TICE | phase 3 | Live attenuated vaccine / Immunotherapy | Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation | Oncology / Immunology |
Therapeutic area mix
- Oncology / Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Alliance for Clinical Trials in Oncology · 1 shared drug class
- Massachusetts General Hospital · 1 shared drug class
- Memorial Sloan Kettering Cancer Center · 1 shared drug class
- Nottingham University Hospitals NHS Trust · 1 shared drug class
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 shared drug class
- TASK Applied Science · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Verity Pharmaceuticals Inc.:
- Verity Pharmaceuticals Inc. pipeline updates — RSS
- Verity Pharmaceuticals Inc. pipeline updates — Atom
- Verity Pharmaceuticals Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Verity Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/verity-pharmaceuticals-inc. Accessed 2026-05-16.